What’s more, we found that higher KIF20A expression was correlated with a significantly shorter OS and PFS in the advanced clinical stage III-IV NPC patients who treated with CCRT subgroup (P = 0.028 and P = 0.040, respectively; Fig 5C and 5D).The data demonstrated that the advanced clinical stage III-IV NPC patients who overexpress KIF20A still had a poor survival even after had treated with CCRT. This evidence concerns the gene KIF20A and nasopharyngeal carcinoma.